Goodpasture syndrome: An updated overview for healthcare professionals
Keywords:
Goodpasture syndrome, anti-GBM disease, pulmonary hemorrhage, glomerulonephritis, autoimmune disorderAbstract
Background: Goodpasture syndrome is an autoimmune disorder characterized by the presence of anti-glomerular basement membrane (anti-GBM) antibodies, leading to significant lung and kidney complications, particularly pulmonary hemorrhage and glomerulonephritis. The disease has a poor prognosis if not promptly treated, making early identification and intervention crucial. Aim: This article aims to provide an updated overview of Goodpasture syndrome, highlighting its etiology, epidemiology, pathophysiology, diagnosis, and treatment approaches, to enhance healthcare professionals' understanding and management of this condition. Methods: A comprehensive review of current literature on Goodpasture syndrome was conducted, focusing on its clinical presentation, histopathological findings, and advancements in diagnostic techniques. The article discusses relevant immunological aspects, genetic predispositions, and the significance of serological testing in diagnosis. Results: The incidence of Goodpasture syndrome is estimated at 0.5 to 1.8 cases per million annually, with a bimodal age distribution. Genetic factors, particularly the presence of specific human leukocyte antigens (HLAs), play a significant role in disease susceptibility. The pathophysiology involves circulating autoantibodies targeting type IV collagen, leading to crescentic glomerulonephritis and pulmonary damage. Renal biopsy remains the gold standard for diagnosis, with immunofluorescence microscopy revealing characteristic linear immunoglobulin deposits.
Downloads
References
Reggiani F, L'Imperio V, Calatroni M, Pagni F, Sinico RA. Goodpasture syndrome and anti-glomerular basement membrane disease. Clin Exp Rheumatol. 2023 Apr;41(4):964-974. DOI: https://doi.org/10.55563/clinexprheumatol/tep3k5
Ooi JD, Petersen J, Tan YH, Huynh M, Willett ZJ, Ramarathinam SH, Eggenhuizen PJ, Loh KL, Watson KA, Gan PY, Alikhan MA, Dudek NL, Handel A, Hudson BG, Fugger L, Power DA, Holt SG, Coates PT, Gregersen JW, Purcell AW, Holdsworth SR, La Gruta NL, Reid HH, Rossjohn J, Kitching AR. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature. 2017 May 11;545(7653):243-247. DOI: https://doi.org/10.1038/nature22329
Yang R, Cui Z, Zhao J, Zhao MH. The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clin Immunol. 2009 Nov;133(2):245-50. DOI: https://doi.org/10.1016/j.clim.2009.07.005
Peto P, Salama AD. Update on antiglomerular basement membrane disease. Curr Opin Rheumatol. 2011 Jan;23(1):32-7. DOI: https://doi.org/10.1097/BOR.0b013e328341009f
Chan AL, Louie S, Leslie KO, Juarez MM, Albertson TE. Cutting edge issues in Goodpasture's disease. Clin Rev Allergy Immunol. 2011 Oct;41(2):151-62. DOI: https://doi.org/10.1007/s12016-010-8222-2
Batal I, Reyes DB, Popham S, Bijol V. Nodular glomerulosclerosis with anti-glomerular basement membrane-like glomerulonephritis; a distinct pattern of kidney injury observed in smokers. Clin Kidney J. 2014 Aug;7(4):361-366. DOI: https://doi.org/10.1093/ckj/sfu064
Cranfield A, Mathavakkannan S. Goodpasture's disease following extracorporeal shock wave lithotripsy: a case report & literature review. Clin Case Rep. 2015 Mar;3(3):160-4. DOI: https://doi.org/10.1002/ccr3.190
Kluth DC, Rees AJ. Anti-glomerular basement membrane disease. J Am Soc Nephrol. 1999 Nov;10(11):2446-53. DOI: https://doi.org/10.1681/ASN.V10112446
Tang W, McDonald SP, Hawley CM, Badve SV, Boudville NC, Brown FG, Clayton PA, Campbell SB, de Zoysa JR, Johnson DW. Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int. 2013 Mar;83(3):503-10. DOI: https://doi.org/10.1038/ki.2012.375
Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003 Mar;63(3):1164-77. DOI: https://doi.org/10.1046/j.1523-1755.2003.00843.x
Salama AD, Levy JB, Lightstone L, Pusey CD. Goodpasture's disease. Lancet. 2001 Sep 15;358(9285):917-20. DOI: https://doi.org/10.1016/S0140-6736(01)06077-9
Pozzi A, Yurchenco PD, Iozzo RV. The nature and biology of basement membranes. Matrix Biol. 2017 Jan;57-58:1-11. DOI: https://doi.org/10.1016/j.matbio.2016.12.009
Pedchenko V, Kitching AR, Hudson BG. Goodpasture's autoimmune disease - A collagen IV disorder. Matrix Biol. 2018 Oct;71-72:240-249. DOI: https://doi.org/10.1016/j.matbio.2018.05.004
Cui Z, Zhao J, Jia XY, Zhu SN, Zhao MH. Clinical features and outcomes of anti-glomerular basement membrane disease in older patients. Am J Kidney Dis. 2011 Apr;57(4):575-82 DOI: https://doi.org/10.1053/j.ajkd.2010.09.022
Anguiano L, Kain R, Anders HJ. The glomerular crescent: triggers, evolution, resolution, and implications for therapy. Curr Opin Nephrol Hypertens. 2020 May;29(3):302-309. DOI: https://doi.org/10.1097/MNH.0000000000000596
Arimura Y, Muso E, Fujimoto S, Hasegawa M, Kaname S, Usui J, Ihara T, Kobayashi M, Itabashi M, Kitagawa K, Hirahashi J, Kimura K, Matsuo S. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016 Jun;20(3):322-41. DOI: https://doi.org/10.1007/s10157-015-1218-8
Walsh M, Merkel PA, Peh CA, Szpirt W, Guillevin L, Pusey CD, De Zoysa J, Ives N, Clark WF, Quillen K, Winters JL, Wheatley K, Jayne D., PEXIVAS Investigators. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials. 2013 Mar 14;14:73. DOI: https://doi.org/10.1186/1745-6215-14-73
McAdoo SP, Tanna A, Hrušková Z, Holm L, Weiner M, Arulkumaran N, Kang A, Satrapová V, Levy J, Ohlsson S, Tesar V, Segelmark M, Pusey CD. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017 Sep;92(3):693-702. DOI: https://doi.org/10.1016/j.kint.2017.03.014
Zhao J, Yan Y, Cui Z, Yang R, Zhao MH. The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity. Hum Immunol. 2009 Jun;70(6):425-9. DOI: https://doi.org/10.1016/j.humimm.2009.04.004
Gluhovschi C, Gadalean F, Velciov S, Nistor M, Petrica L. Three Diseases Mediated by Different Immunopathologic Mechanisms-ANCA-Associated Vasculitis, Anti-Glomerular Basement Membrane Disease, and Immune Complex-Mediated Glomerulonephritis-A Common Clinical and Histopathologic Picture: Rapidly Progressive Crescentic Glomerulonephritis. Biomedicines. 2023 Nov 06;11(11) DOI: https://doi.org/10.3390/biomedicines11112978
Berden AE, Ferrario F, Hagen EC, Jayne DR, Jennette JC, Joh K, Neumann I, Noël LH, Pusey CD, Waldherr R, Bruijn JA, Bajema IM. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010 Oct;21(10):1628-36. DOI: https://doi.org/10.1681/ASN.2010050477
Kalluri R, Wilson CB, Weber M, Gunwar S, Chonko AM, Neilson EG, Hudson BG. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol. 1995 Oct;6(4):1178-85. DOI: https://doi.org/10.1681/ASN.V641178
McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2017 Jul 07;12(7):1162-1172. DOI: https://doi.org/10.2215/CJN.01380217
Heitz M, Carron PL, Clavarino G, Jouve T, Pinel N, Guebre-Egziabher F, Rostaing L. Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease. BMC Nephrol. 2018 Sep 20;19(1):241. DOI: https://doi.org/10.1186/s12882-018-1038-7
Greenhall GH, Salama AD. What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J. 2015 Apr;8(2):143-50. DOI: https://doi.org/10.1093/ckj/sfv008
Syeda UA, Singer NG, Magrey M. Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review. Semin Arthritis Rheum. 2013 Jun;42(6):567-72. DOI: https://doi.org/10.1016/j.semarthrit.2012.10.007
Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001 Jun 05;134(11):1033-42. DOI: https://doi.org/10.7326/0003-4819-134-11-200106050-00009
Apaydin S. The treatment of ANCA-associated rapidly-progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis. Transfus Apher Sci. 2018 Feb;57(1):8-12. DOI: https://doi.org/10.1016/j.transci.2018.02.007
Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, Le Guellec C, Lafont T, Grand A, Rostaing L, Chatelut E, Pourrat J. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol. 2013 Nov;76(5):734-40. DOI: https://doi.org/10.1111/bcp.12098
Pacheco M, Silva JE, Silva C, Soares N, Almeida J. Double-Positive Anti-GBM and ANCA-MPO Vasculitis Presenting With Crescentic Glomerulonephritis. Cureus. 2021 May 02;13(5):e14806. DOI: https://doi.org/10.7759/cureus.14806
Published
How to Cite
Issue
Section
Copyright (c) 2024 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
